Skip to main content
PeptideSciences101NH2COOH
PeptideSciences101

Generic Wegovy? Mylan Challenges Novo Nordisk’s Semaglutide Patent

Published October 2, 2026. A complaint states a party's claims; filing it does not establish that those claims are correct.

What Mylan filed

Mylan filed a declaratory-judgment complaint against Novo Nordisk in Delaware on September 23, 2026, case No. 1:26-cv-01192. It seeks findings of noninfringement and invalidity of U.S. Patent 12,551,536, listed for Wegovy.[1]

The complaint identifies ANDA 217705 for proposed semaglutide injection pens and relates the new case to existing Delaware litigation, No. 23-101-CFC. These are Mylan's positions, not judicial findings. The filing itself grants neither FDA approval nor permission to launch.[1]

Generic approval and compounding follow different pathways

FDA describes an abbreviated new drug application (ANDA) as a submission for review and potential approval of a generic product. Generic applicants must establish comparability to the reference drug and satisfy the applicable approval requirements. The Hatch-Waxman framework also allows patent challenges before marketing.[2]

PathwayWhat it means
Approved branded drugA finished product with FDA approval.
Generic via ANDAA product pursuing its own FDA approval, with patent and exclusivity questions also relevant to marketing.
Compounding under 503A or 503BPreparation subject to statutory conditions; the compounded product is not FDA-approved.

FDA explicitly distinguishes approved generics from compounded drugs. Compounding can meet particular patient needs, but it does not confer generic approval, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.[3]

What readers should take away

Our interpretation: describe this development as a patent challenge, not a generic-launch announcement. A useful follow-up requires a substantive court order or a verified FDA approval record. This article makes no prediction about availability, launch timing, or price.

Calling a compounded product “generic Wegovy” blurs an important regulatory distinction. Readers should ask which finished product is being offered, whether it has FDA approval, and which legal pathway applies.

References

  1. Mylan v. Novo Nordisk — filed complaint, September 23, 2026, D. Del. No. 1:26-cv-01192 (public copy hosted by Pearce IP)
  2. FDA — Abbreviated New Drug Application (ANDA)
  3. FDA — Compounding and the FDA: Questions and Answers

Educational reference only. Nothing on this page constitutes legal or medical advice. Claims in a complaint are distinguished from judicial findings; regulatory status can change.